Magnetic resonance imaging features of breast cancer according to intrinsic subtypes: correlations with neoadjuvant chemotherapy effects

被引:21
作者
Kawashima, Hiroko [1 ,2 ]
Inokuchi, Masafumi [2 ]
Furukawa, Hiroyuki [2 ]
Ikeda, Hiroko [3 ]
Kitamura, Seiko [3 ]
机构
[1] Kanazawa Univ, Grad Sch Med Sci, Dept Quantum Med Technol, Kanazawa, Ishikawa 9200942, Japan
[2] Kanazawa Univ Hosp, Sect Breast Oncol, Kanazawa, Ishikawa 9208641, Japan
[3] Kanazawa Univ Hosp, Div Pathol, Kanazawa, Ishikawa 9208641, Japan
关键词
Magnetic resonance imaging; Breast cancer; Intrinsic subtype; Neoadjuvant chemotherapy; INTERNATIONAL EXPERT PANEL; PRIMARY SYSTEMIC TREATMENT; MRI; RECOMMENDATIONS; MAMMOGRAPHY; SONOGRAPHY; ACCURACY; THERAPY;
D O I
10.1186/2193-1801-3-240
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose: The purpose of this study was to evaluate the magnetic resonance imaging (MRI) features of breast cancer according to intrinsic subtypes and to investigate whether the MRI and immunohistochemical findings were related to neoadjuvant chemotherapy (NAC) effects. Materials and methods: The MRI in 116 women with breast cancers who underwent NAC was reviewed. The mass margin, presence of intratumoral necrosis, tumor extension around the mass, relative signal enhancement (RSE), and kinetic curve pattern were analyzed. We investigated the possible correlations between MRI findings and the effects of NAC. Results: An irregular mass margin was significantly associated with luminal-A cancers, while a smooth mass margin was associated with human epidermal growth factor receptor2 (HER2) cancers. Intratumoral necrosis was significantly associated with triple-negative cancers. Tumor extension around the mass was significantly infrequent in luminal-B cancers and frequent in HER2 cancers. Luminal-B and HER2 cancers showed a significantly higher RSE at 2 min than Luminal-A cancers. Estrogen receptor (ER)-positive cancers, HER2-negative cancers, and presence of intratumoral necrosis were significantly associated with the NAC non-response. Conclusions: Several MR features can be used to predict the intrinsic subtype of breast cancers. ER-positivity, HER2-negativity, and presence of intratumoral necrosis were significantly associated with NAC non-response.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 33 条
[1]  
Abraham DC, 1996, CANCER, V78, P91, DOI 10.1002/(SICI)1097-0142(19960701)78:1<91::AID-CNCR14>3.0.CO
[2]  
2-2
[3]   Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: Preliminary results [J].
Abramson, Richard G. ;
Li, Xia ;
Hoyt, Tamarya Lea ;
Su, Pei-Fang ;
Arlinghaus, Lori R. ;
Wilson, Kevin J. ;
Abramson, Vandana G. ;
Chakravarthy, A. Bapsi ;
Yankeelov, Thomas E. .
MAGNETIC RESONANCE IMAGING, 2013, 31 (09) :1457-1464
[4]   Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy [J].
Akazawa, K ;
Tamaki, Y ;
Taguchi, T ;
Tanji, Y ;
Miyoshi, Y ;
Kim, SJ ;
Ueda, S ;
Yanagisawa, T ;
Sato, Y ;
Tamura, S ;
Noguchi, S .
BREAST JOURNAL, 2006, 12 (02) :130-137
[5]  
[Anonymous], 2012, GEN RULES CLIN PATHO
[6]  
[Anonymous], 2003, BREAST IM REP DAT SY
[7]  
Bae MS, 2014, ACTA RADIOL
[8]   Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI [J].
Balu-Maestro, C ;
Chapellier, C ;
Bleuse, A ;
Chanalet, I ;
Chauvel, C ;
Largillier, R .
BREAST CANCER RESEARCH AND TREATMENT, 2002, 72 (02) :145-152
[9]   Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? [J].
Brenton, JD ;
Carey, LA ;
Ahmed, AA ;
Caldas, C .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (29) :7350-7360
[10]   Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer [J].
Chollet, P ;
Amat, S ;
Cure, H ;
de Latour, M ;
Le Bouedec, G ;
Mouret-Reynier, MA ;
Ferriere, JP ;
Achard, JL ;
Dauplat, J ;
Penault-Llorca, F .
BRITISH JOURNAL OF CANCER, 2002, 86 (07) :1041-1046